Tip: To match a phrase, use quotation marks around the search term. eg. "Parliamentary Estate"


View sample alert
Written Question
Cancer: Screening
29 Sep 2021

Questioner: Peter Gibson (CON - Darlington)

Question

To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that all trans people are included in necessary cancer screenings applicable to them.

Answered by Maria Caulfield

Public Health England (PHE) has published a leaflet advising both trans men and women to contact their general practitioner (GP) about breast screening, as long-term hormone therapy may increase their risk of developing breast cancer. The leaflet also advises that transgender men registered as male should ask their GP to update their records to ensure that they are invited for cervical screening.

PHE also provides advice to health professionals on working with trans men and women, to ensure that patients feel comfortable or can access services in other ways if necessary.


Written Question
Breast Cancer: Solihull
16 Sep 2021

Questioner: Saqib Bhatti (CON - Meriden)

Question

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that there are an adequate number of radiologists in clinics and hospitals in the Solihull Borough available to scan women at risk of breast cancer.

Answered by Jo Churchill

Warwickshire Solihull and Coventry Breast Screening service has received funding from NHS England and NHS Improvement to increase its mammography, radiography and radiology staffing capacity. Further to this locally targeted action, regional partners including Health Education England and NHS England and NHS Improvement have undertaken a workforce review of breast screening to tackle current shortages of trained staff. This will support all breast screening services, including the Warwickshire Solihull and Coventry service to have sufficient and sustainable staffing into the future.


Written Question
Breast Cancer: Solihull
16 Sep 2021

Questioner: Saqib Bhatti (CON - Meriden)

Question

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the provision of breast cancer screening in the Solihull Borough after the four-month closure of the Warwickshire Solihull and Coventry Breast Cancer Screening Service as a result of the covid-19 outbreak.

Answered by Jo Churchill

The Warwickshire Solihull and Coventry Breast Cancer Screening Service is working to screen all women who have missed an appointment by 31 March 2022, with NHS England and NHS Improvement monitoring progress.

The service has been able to gradually increase its capacity through the offer of open invitations rather than fixed time appointments and increasing the levels of permanent, third party and trainee staff, allowing the service to offer screening at additional times.


Written Question
Trodelvy
13 Sep 2021

Questioner: Mick Whitley (LAB - Birkenhead)

Question

To ask the Secretary of State for Health and Social Care, if he will meet with people affected by metastatic triple-negative breast cancer to discuss the potential of the drug Sacituzumab Govitecan, marketed as Trodelvy, to improve (a) the quality of life and (b) the prognoses of people diagnosed with that condition.

Answered by Jo Churchill

We have no current plans to do so. The National Institute for Health and Care Excellence is currently appraising Trodelvy (Sacituzumab govitecan) for the treatment of metastatic triple negative breast cancer and expects to publish guidance for the National Health Service in June 2022.


Written Question
Trodelvy
13 Sep 2021

Questioner: Mick Whitley (LAB - Birkenhead)

Question

To ask the Secretary of State for Health and Social Care, what steps his Department can take to accelerate the approval of the drug Sacituzumab Govitecan, marketed as Trodelvy, by the Medicine and Healthcare products Regulatory Authority.

Answered by Nadine Dorries

The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of the importance of Trodelvy and is participating in several new schemes designed to speed up its availability.

Earlier this year, a licence application for Trodelvy in metastatic triple negative breast cancer was filed in the United Kingdom as part of Project Orbis. The United States approval is being considered and the MHRA is currently evaluating the application for Trodelvy.


Written Question
Cancer: Screening
8 Sep 2021

Questioner: Rachael Maskell (LAB - York Central)

Question

To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of cancer screening tests that have taken place for each type of cancer in each of the last five years.

Answered by Jo Churchill

Annual statistics for the three National Health Service cancer screening programmes are available online. The data for each of the last five years is reproduced in the following table:

NHS Cancer Screening Programme (number of tests, millions)

Year

Bowel

Cervical

Breast

2015-16

2.41

3.13

2.16

2016-17

2.61

3.21

2.20

2017-18

2.53

3.22

2.14

2018-19

2.74

3.47

2.23

2019-20

2.81

3.23

2.12

Source: www.digital.nhs.uk, https://www.gov.uk/government/publications/nhs-screening-programmes-annual-report, https://www.gov.uk/government/collections/nhs-population-screening-programmes-kpi-reports


Written Question
Trodelvy
8 Sep 2021

Questioner: Zarah Sultana (LAB - Coventry South)

Question

To ask the Secretary of State for Health and Social Care, what recent representations he has made to representatives of the Medicines and Healthcare products Regulatory Agency (MHRA) on accelerating the approval of Trodelyn for treating metastatic triple negative breast cancer (TNBC).

Answered by Nadine Dorries

No such representations have been made. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for independently assessing the efficacy and safety of drugs before approval.


Written Question
Cancer: Medical Treatments
2 Aug 2021

Questioner: Lord Browne of Belmont (DUP - Life peer)

Question

To ask Her Majesty's Government what recent progress they have made in ensuring equality in cancer treatment across England.

Answered by Lord Bethell

Reducing unwarranted variation in cancer treatment and outcomes is a strategic priority for the National Health Service Cancer Programme. To support cancer services and target local and national actions for improvement, monthly equality data showing first treatment rates by ethnicity, deprivation, sex and age is directly informing the restoration and recovery of cancer services. This includes targeted messaging in the national ‘Help us help you’ campaign to support people coming forward with symptoms indicative of cancer to their general practitioner. In May 2021, urgent general practitioner referrals were 14% higher than in May 2019.

NHS England and NHS Improvement have put in place single national commissioning arrangements for a number of cancer treatments to mitigate the risk of unwarranted variation in terms of access and clinical outcomes. Audits are currently being carried out for lung, bowel, prostate and oesophageal cancers and for breast cancer in older people to drive improvements in care and ensure equity. Five new clinical audits will be commissioned for ovarian, pancreatic, non-hodgkin lymphoma, kidney and metastatic breast cancer to ensure that care is being provided in line with standards and reduce variations.


Written Question
Medical Treatments
26 Jul 2021

Questioner: Vicky Foxcroft (LAB - Lewisham, Deptford)

Question

To ask the Secretary of State for Health and Social Care, how many NICE technology appraisals have been delayed as a result of operational challenges in 2021; and if he will place in the Library a list of the affected appraisals.

Answered by Jo Churchill

The 19 topics listed as follows have been delayed as a result of operational challenges in 2021.

- Tuberous sclerosis complex (seizures) – cannabidiol;

- Waldenstrom's macroglobulinaemia – zanubrutinib;

- Head and neck cancer (untreated, metastatic squamous cell) - nivolumab (with ipilimumab);

- Breast cancer (triple negative) - pembrolizumab (neoadjuvant, with chemotherapy);

- Renal cell carcinoma (metastatic, untreated) - nivolumab (with cabozantinib);

- Multiple sclerosis (relapsing-remitting) - diroximel fumarate;

- Upadacitinib for treating active psoriatic arthritis after inadequate response to disease modifying anti-rheumatic drugs (DMARDs);

- Gastric cancer (resect) - pembrolizumab (with chemotherapy and surgery);

- Dermatitis (atopic, moderate, severe, aged 12 and over) – upadacitinib;

- Tralokinumab for treating moderate to severe atopic dermatitis;

- Dermatitis (atopic, moderate, severe, aged 12 and over) – abrocitinib;

- Cough (refractory, chronic) – gefapixant;

- Renal cell carcinoma - pembrolizumab (adjuvant);

- Polyps (nasal), rhinosinusitis (chronic, severe) – mepolizumab;

- Ulcerative colitis (moderate, severe) – ozanimod;

- Ankylosing spondylitis (active) – upadacitinib;

- Lung cancer (non-small-cell, resected) - atezolizumab (adjuvant);

- Ankylosing spondylitis (active) – tofacitinib; and

- Hepatocellular carcinoma (advanced, treated) - cabozantinib (review of technology appraisal 582).


Written Question
Breast Cancer: Screening
1 Jul 2021

Questioner: Jonathan Ashworth (LAB - Leicester South)

Question

To ask the Secretary of State for Health and Social Care, what his plans are for the recovery of breast screening services from the covid-19 outbreak by the end of the 2021-22 financial year.

Answered by Jo Churchill

NHS England and NHS Improvement have advised that National Health Service breast screening providers are working to manage screening invitation and diagnostic backlogs. Amongst a range of initiatives to address recovery, breast screening offices (BSOs) are running extra screening sessions and utilising open invitations to fully optimise available appointments. Some BSOs have already cleared the backlog and others are aiming to do so by the end of 2021/22.


Written Question
Cancer: West Midlands
1 Jul 2021

Questioner: Andrew Mitchell (CON - Sutton Coldfield)

Question

To ask the Secretary of State for Health and Social Care, what steps his Department is taking in the West Midlands to ensure that the backlog for cancer treatment is prioritised.

Answered by Jo Churchill

Cancer treatments in the West Midlands have continued throughout the pandemic with little reduction in capacity for chemotherapy and radiotherapy treatments. Work is now ongoing to prioritise surgery and diagnostic procedures, including additional endoscopy resource, further development of rapid diagnostic centres and implementation of community diagnostic hubs. The implementation of breast pain pathways should reduce demand on cancer services and help focus capacity on where it is needed. The elective recovery programme is underway and is focussing on the reduction of backlogs in the highest priority categories of patients, which includes cancer patients.


Written Question
Cancer: Screening
18 Jun 2021

Questioner: Mark Menzies (CON - Fylde)

Question

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of people awaiting a routine invitation for (a) bowel screening, (b) breast screening and (c) cervical screening in England.

Answered by Jo Churchill

NHS England and NHS Improvement have advised that all National Health Service cancer screening programmes are operational and sending out screening invitations at, or above, pre-pandemic levels. There is no backlog for the cervical screening programme and NHS England and NHS Improvement continue to address backlogs in the breast and bowel screening programmes.


Written Question
Breast Cancer: Screening
21 May 2021

Questioner: Anthony Browne (CON - South Cambridgeshire)

Question

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of offering mammography screening on a biennial basis instead of a three-year interval.

Answered by Jo Churchill

The United Kingdom National Screening Committee (UK NSC) is not currently considering the potential merits of offering mammography screening on a biennial basis instead of the current three-year interval. The NHS Breast Screening Programme is currently focussed on inviting all eligible women to participate in breast screening for screening that may have been delayed due to COVID-19.

A proposal to change the current screening interval from three yearly to biennial would be for the UK NSC to consider through its programme modification proposal process, which is available at the following link:

https://www.gov.uk/government/publications/uk-nsc-evidence-review-process


Written Question
Trodelvy
29 Apr 2021

Questioner: Bell Ribeiro-Addy (LAB - Streatham)

Question

To ask the Secretary of State for Health and Social Care, if he will allow accelerated approval and access to the breast cancer drug Trodelvy, to treat people with serious metastatic triple-negative breast cancer.

Answered by Nadine Dorries

It has not proved possible to respond to the hon. Member in the time available before prorogation.


Written Question
Breast Cancer: Clinical Trials
27 Apr 2021

Questioner: Philippa Whitford (SNP - Central Ayrshire)

Question

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 June 2020 to Question 56022, what plans his Department has to recover and restart recruitment to breast cancer clinical trials.

Answered by Jo Churchill

The Department’s National Institute for Health Research (NIHR) is supporting the National Health Service to deliver clinical research through the Clinical Research Network (CRN).

The NIHR’s CRN reports that of the 92 breast cancer clinical trials that it was supporting on 21 May 2020, 36 or 39% were paused as a result of the COVID-19 pandemic. As of 15 April 2021, 30 or 83% of these paused breast cancer trials have restarted and 30 new breast cancer trials have entered the portfolio since 21 May 2020.

To enable clinical research studies that have been paused to restart and recruit successfully, including breast cancer trials, plans are being developed to manage the delivery of non-COVID-19 studies to ensure successful recovery of the portfolio. Details of these plans will be published shortly.